The Zio XT wearable ECG patch yielded an Afib detection rate of 5.3% by 6 months, compared with 0.5% achieved through standard care (RR 11.2, 95% CI 2.7-47.1), according to researchers led by David Gladstone, MD, PhD, of Sunnybrook Research Institute at the University of Toronto.

SCREEN-AF participants were 856 older community-dwelling individuals with hypertension and no known Afib who were judged to be at moderate or high risk for stroke. Mean age was 80.0 years, and 56.9% of participants were women.

The trial was conducted in Canada and Germany at 48 primary care practices in 2015-2019.

 

Results were less promising for intermittent oscillometric screening. A deluge of false positives and missed Afib episodes gave this form of screening a sensitivity of 35.0%, specificity of 81.0%, positive predictive value of 8.9%, and negative predictive value of 95.9%.

Tags

Therapeutic Modality ,Cardiac rehabillitation,Cardiovascular Surgery,Monitoring and other Devices ,Implantable Devices,Interventional Cardiology,Pharmacotherapeutics,Cardiac Rehab,TRHB_others,Bypass,Cardiac Transplantation,TCVS_others,Defibrillators,Ventricular assist device,TMOD_others,Pacemaker Malfunction,Pacemaker Syndrome,Inferior Vena Cava Filters,Cardioverter-Defibrillators,TIMP_others,Bare metal stent,Drug Eluting Stent,Percutaneous Coronary Intervention,Trans catheter Therapy ,TINC_others,Thrombolysis in Myocardial Infarction (TIMI) Score,Digitalis,TPHT_others